ROG

Roche trial of drug to treat COVID-19-related pneumonia fails

Credit: REUTERS/ARND WIEGMANN

A late-stage clinical trial of Roche's Actemra/RoActemra drug to treat patients hospitalised with severe COVID-19-related pneumonia failed, the drugmaker said on Wednesday.

ZURICH, July 29 (Reuters) - A late-stage clinical trial of Roche's ROG.S Actemra/RoActemra drug to treat patients hospitalised with severe COVID-19-related pneumonia failed, the drugmaker said on Wednesday.

The "COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality," Roche said.

(Reporting by John Revill; Editing by Michael Shields)

((John.Revill@thomsonreuters.com; +41 58306 7022; Reuters Messaging: john.revill.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ROG

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More